European Union - English - EMA (European Medicines Agency)

mcm vaccine b.v. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens: pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae types 2 and 3, hepatitis b surface antigen produced in yeast cells, poliovirus (inactivated): type 1 (mahoney), type 2 (mef-1), type 3 (saukett) produced in vero cells/ haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to meningococcal protein. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - vaccines - vaxelis (dtap-hb-ipv-hib) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive diseases caused by haemophilus influenzae type b (hib). the use of vaxelis should be in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sitagliptin - diabetes mellitus, type 2 - drugs used in diabetes - for patients with type-2 diabetes mellitus, tesavel is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a pparγ agonist (i.e. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination witha sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control;a peroxisome-proliferator-activated-receptor-gamma (pparγ) agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.tesavel is also indicated as add on to insulin (with or without metformin) when diet and exercise plus stable dosage of insulin do not provide adequate glycaemic control.

Canada - English - Health Canada

xediton pharmaceuticals inc - pindolol - tablet - 5mg - pindolol 5mg - beta-adrenergic blocking agents

Canada - English - Health Canada

tribute pharmaceuticals canada inc - pindolol - tablet - 15mg - pindolol 15mg - beta-adrenergic blocking agents

Canada - English - Health Canada

xediton pharmaceuticals inc - pindolol - tablet - 10mg - pindolol 10mg - beta-adrenergic blocking agents

Canada - English - Health Canada

biomed pharma - carbamazepine - tablet - 200mg - carbamazepine 200mg - miscellaneous anticonvulsants

Canada - English - Health Canada

purdue pharma - hydromorphone hydrochloride - liquid - 10mg - hydromorphone hydrochloride 10mg - opiate agonists

Canada - English - Health Canada

novartis pharmaceuticals canada inc - carbamazepine - tablet (chewable) - 100mg - carbamazepine 100mg - miscellaneous anticonvulsants

Canada - English - Health Canada

novartis pharmaceuticals canada inc - carbamazepine - tablet (chewable) - 200mg - carbamazepine 200mg - miscellaneous anticonvulsants

Canada - English - Health Canada

purdue pharma - hydromorphone hydrochloride - liquid - 1mg - hydromorphone hydrochloride 1mg - opiate agonists